Compare BAFN & MRKR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BAFN | MRKR |
|---|---|---|
| Founded | 1999 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 26.6M | 23.0M |
| IPO Year | 2021 | 2010 |
| Metric | BAFN | MRKR |
|---|---|---|
| Price | $7.30 | $1.56 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 17.8K | ★ 152.9K |
| Earning Date | 04-30-2026 | 05-14-2026 |
| Dividend Yield | ★ 1.10% | N/A |
| EPS Growth | N/A | ★ 33.61 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $644.02 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.80 | $0.81 |
| 52 Week High | $17.16 | $4.07 |
| Indicator | BAFN | MRKR |
|---|---|---|
| Relative Strength Index (RSI) | 66.06 | 55.59 |
| Support Level | $6.31 | $1.33 |
| Resistance Level | $8.26 | $1.69 |
| Average True Range (ATR) | 0.49 | 0.13 |
| MACD | 0.12 | 0.04 |
| Stochastic Oscillator | 93.90 | 61.67 |
BayFirst Financial Corp is a bank holding company, it generates its revenue from interest on loans and the gain-on-sale income derived from the sale of loans into the secondary market. The company serves a broad spectrum of individuals, families, and small businesses, supported by national business lines in residential and SBA lending and technology platforms. The primary source of funding for its loans is deposits. BayFirst measures performance through net interest income after provision for loan losses, return on average assets, and return on average common equity, while maintaining appropriate regulatory leverage and risk-based capital ratios. The company has various segment such as Real Estate(Residential, Commercial, and Construction & Land), Commercial and Industrial, Consumer.
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets.